COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,442 Articles (22,835 medRxiv, 8,607 bioRxiv)

Most recent first Previous |  Page 953: Articles 9521-9530  | Next

The COVID-19 Community Research Partnership: Objectives, Study Design, Baseline Recruitment, and Retention
The COVID-19 Community Research Partnership Study Group, , Sanders, J.
10.1101/2022.02.09.22270272 — Posted: 2022-02-10
Machine Learning Generalizability Across Healthcare Settings: Insights from multi-site COVID-19 screening
Yang, J., Soltan, A. A., Clifton, D. A.
10.1101/2022.02.09.22269744 — Posted: 2022-02-10
Implementation and economic effects of local non-pharmaceutical interventions
Godoy, A. A., Grotting, M. W.
10.1101/2022.02.10.22270783 — Posted: 2022-02-10
Immune responses after twofold SARS-CoV-2 immunisation in elderly residents and Health Care Workers in nursing homes and homes with assisted living support - Proposal for a correlate of protection
Schiffner, J., Eisemann, N., Baltus, H., Jensen, S., Wunderlich, K., Schuesseler, S., Eicker, C., Teegen, B., Boniakowsky, D., Solbach, W., Mischnik, A.
10.1101/2022.02.09.22270747 — Posted: 2022-02-10
Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals
Saraf, S., Zhu, X., Shrestha, R., Bonny, T. S., Baker, O. R., Beck, E. J., Fernandez, R. E., Eby, Y., Akinde, O., Ruff, J. E., Caturegli, P., Redd, A. D., Bloch, E. M., Quinn, T. C., Tobian, A. A., Laeyendecker, O.
10.1101/2022.02.09.22270718 — Posted: 2022-02-10
First cases of infection with the 21L/BA.2 Omicron variant in Marseille, France
Colson, P., Delerce, J., Beye, M., LEVASSEUR, A., Boschi, C., Houhamdi, L., Tissot-Dupont, H., Yahi, N., Million, M., LA SCOLA, B., Fantini, J., Raoult, D., Fournier, P.-E.
10.1101/2022.02.08.22270495 — Posted: 2022-02-10
Safety and Efficacy of Preventative COVID Vaccines: The StopCoV Study
Walmsley, S., Szadkowski, L., Wouters, B., Clarke, R., Colwill, K., Rochon, P., Brudno, M., Ravindran, R., Raboud, J., McGeer, A., Oza, A., Graham, C., Silva, A., Manase, D., Parente, L., Simpson, J., Dayam, R. M., Pasculescu, A., Gingras, A.-C.
10.1101/2022.02.09.22270734 — Posted: 2022-02-10
Innovative Randomized Phase 1 Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir
Singh, R. S. P., Toussi, S. S., Hackman, F., Chan, P. L., Rao, R., Allen, R., Van Eyck, L., Pawlak, S., Kadar, E. P., Clark, F., Shi, H., Anderson, A. S., Binks, M., Menon, S., Nucci, G., Bergman, A.
10.1101/2022.02.08.22270649 — Posted: 2022-02-10
Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico
Ponce-de-Leon, S., Torres, M., Soto-Ramirez, L. E., Calva, J. J., Santillan-Doherty, P., Carranza-Salazar, D. E., Carreno, J. M., Carranza, C., Juarez, E., Carreto-Binaghi, L. E., Ramirez-Martinez, L., Paz-De la Rosa, G., Vigueras-Moreno, R., Ortiz-Stern, A., Lopez-Vidal, Y., Macias, A. E., Torres-Flores, J., Rojas-Martinez, O., Suarez-Martinez, A., Peralta-Sanchez, G., Kawabata, H., Gonzalez-Dominguez, I., Martinez-Guevara, J. L., Sun, W., Sarfati-Mizrahi, D., Soto-Priante, E., Chagoya-Cortes, H. E., Lopez-Macias, C., Castro-Peralta, F., Palese, P., Garcia-Sastre, A., Krammer, F., Lozano-Dubernard, B.
10.1101/2022.02.08.22270676 — Posted: 2022-02-09
DMARD disruption, disease flare, and prolonged symptom duration after acute COVID-19 among participants with rheumatic disease: A prospective study
DiIorio, M., Cook, C. E., Vanni, K. M. M., Patel, N. J., D'Silva, K. M., Fu, X., Wang, J., Prisco, L. C., Kowalski, E., Zaccardelli, A., Martin, L. W., Qian, G., Hsu, T. Y.- T., Wallace, Z. S., Sparks, J. A.
10.1101/2022.02.08.22270696 — Posted: 2022-02-09

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).